Glioblastoma, an aggressive and deadly brain cancer that killed John McCain, Ted Kennedy and Beau Biden, hasn’t had a new treatment option since 2005. But at this year’s annual meeting of the American Society of Clinical Oncology, Michael Ciesielski, a professor of neurosurgery at Roswell Park Comprehensive Cancer Center, presented findings from the completed phase 2a study of SurVaxM. Ciesielski said he has been encouraged by the results as the drug has progressed through the clinical trial process. “We’ve had great data along the way. Some of the patients we treated very early on had a prognosis of maybe three to six months, and standard available therapies had failed these patients,” Ciesielski said. “Some of these patients ended up surviving for over a year. Some were with us six years later, after having recurrent glioblastoma. That’s unheard of.”
NCPA
